AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Up 5.8% in November

AnaptysBio, Inc. (NASDAQ:ANAB) was the target of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 7,100,000 shares, an increase of 5.8% from the November 15th total of 6,710,000 shares. Approximately 27.3% of the company’s shares are short sold. Based on an average daily volume of 447,100 shares, the days-to-cover ratio is presently 15.9 days.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Wells Fargo & Company dropped their price objective on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Wedbush reissued an “outperform” rating and set a $40.00 price target (down previously from $42.00) on shares of AnaptysBio in a research report on Wednesday, December 11th. UBS Group lifted their price objective on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. dropped their target price on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Finally, BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.09.

AnaptysBio Stock Up 6.8 %

NASDAQ ANAB opened at $16.65 on Tuesday. AnaptysBio has a 52 week low of $14.20 and a 52 week high of $41.31. The company has a 50 day moving average price of $25.56 and a 200 day moving average price of $29.51. The firm has a market cap of $506.64 million, a PE ratio of -2.76 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. On average, equities research analysts anticipate that AnaptysBio will post -6.02 earnings per share for the current fiscal year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This represents a 8.88 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio during the third quarter worth about $49,000. nVerses Capital LLC boosted its stake in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares in the last quarter. Headlands Technologies LLC grew its position in AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 2,600 shares in the last quarter. Finally, Point72 DIFC Ltd raised its holdings in shares of AnaptysBio by 680.5% in the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after buying an additional 5,342 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.